IL22RA1 and COVID-19: Severe COVID-19 patients were characterized by a trend for higher percentages of IL-22R1+ pDC and mDC2 cells and by significantly higher proportions of IL-22R1+ mDC1 cells than non-severe patients (Figures 3A–C).